Skip to content
10-Q

Quarterly Report

CNBX PHARMACEUTICALS INC. CNBX

0001683168-26-000285

← back to feed
Filed
Jan 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Jan 12, 2026 870.77M sh
Shares Diluted Q1 2026 · Nov 30, 2025 732.86M sh
Shares Diluted Q1 2026 · Nov 30, 2024 31.11M sh
Operating Cash Flow Q1 2026 · Nov 30, 2025 −$47.41K
Operating Cash Flow Q1 2026 · Nov 30, 2024 −$39.08K
Cash And Equivalents Q1 2026 · Nov 30, 2025 $7.7K
Cash And Equivalents Q1 2026 · Aug 31, 2025 $15.11K
Stockholders Equity Q1 2026 · Nov 30, 2025 −$2.57M
Stockholders Equity Q1 2026 · Aug 31, 2025 −$2.5M
Stockholders Equity Q1 2026 · Nov 30, 2024 −$2.51M
Stockholders Equity Q1 2026 · Aug 31, 2024 −$2.48M
Current Liabilities Q1 2026 · Nov 30, 2025 $2.58M
Current Liabilities Q1 2026 · Aug 31, 2025 $2.51M
Current Assets Q1 2026 · Nov 30, 2025 $11.16K
Current Assets Q1 2026 · Aug 31, 2025 $18.44K
Total Assets Q1 2026 · Nov 30, 2025 $11.16K
Total Assets Q1 2026 · Aug 31, 2025 $18.44K
Eps Diluted Q1 2026 · Nov 30, 2025 $0.00
Eps Diluted Q1 2026 · Nov 30, 2024 −$0.00
Eps Basic Q1 2026 · Nov 30, 2025 $0.00
Eps Basic Q1 2026 · Nov 30, 2024 −$0.00
Sga Expense Q1 2026 · Nov 30, 2025 $64K
Sga Expense Q1 2026 · Nov 30, 2024 $36.84K
Rd Expense Q1 2026 · Nov 30, 2025 $0
Rd Expense Q1 2026 · Nov 30, 2024 $0
Net Income Q1 2026 · Nov 30, 2025 −$113.72K
Net Income Q1 2026 · Nov 30, 2024 −$34.35K
Operating Income Q1 2026 · Nov 30, 2025 −$64K
Operating Income Q1 2026 · Nov 30, 2024 −$36.84K
Revenue Q1 2026 · Nov 30, 2025 $0
Revenue Q1 2026 · Nov 30, 2024 $0